Format

Send to

Choose Destination
J Clin Neurosci. 2016 Apr;26:75-8. doi: 10.1016/j.jocn.2015.10.008. Epub 2015 Nov 18.

Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Author information

1
Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Felsenstein Medical Research Institut, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: felixbenninger@gmail.com.
2
Felsenstein Medical Research Institut, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
3
Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Abstract

Glial fibrillary acidic protein (GFAP) has been shown to be increased in the cerebrospinal fluid (CSF) of patients suffering from neurological diseases involving the activation of astrocytes, but has not been studied in amyotrophic lateral sclerosis (ALS) patients to our knowledge. CSF samples of patients with definite ALS and of those with other neurological diseases were evaluated for their GFAP concentrations. CSF-GFAP concentrations of patients with ALS were significantly elevated by 53% compared to patients with other neurologic diseases. GFAP might serve as a biomarker in ALS. Our findings support the concept that astrocytes play a role in ALS pathogenesis.

KEYWORDS:

Amyotrophic lateral sclerosis; Astrocytes; Biomarker; GFAP; Motor neuron disease

PMID:
26602604
DOI:
10.1016/j.jocn.2015.10.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center